Latest Wound Care Research from Organogenesis Highlighted at SAWC Fall 2020 Virtual Meeting
Research highlights include a featured presentation, “Comparative Effectiveness of a Bilayered Living Cellular Construct and a Viable Cryopreserved Placental Membrane for the Treatment of Pressure Injuries,” led by
Attendees can view the presentation during the “Advanced Clinical Practice and Emerging Research” abstract session on
As a platinum sponsor of this year’s meeting, Organogenesis will also support the
Visitors to the Organogenesis virtual exhibit booth will have the opportunity to live chat with a Tissue Regeneration Specialist and consult with a Medical Science Liaison about Organogenesis’ innovative product solutions.
“By offering a comprehensive product portfolio driven by evidence and clinical data, Organogenesis continues to advance the standard of care in every phase of the wound healing process,” said
POSTER PRESENTATIONS OF INTEREST INCLUDE:
Dehydrated Placental Allograft (DPA) for the Management of Diabetic Foot Ulcers- A Randomized Controlled
Caporusso JM, Vayser DJ, Cazzell SM,
Effectiveness of a Native Type I Collagen Matrix plus PHMB Antimicrobial in the Treatment of Cutaneous Wounds in a Real World Setting
Effectiveness of a Native Type I Collagen Matrix plus PHMB Antimicrobial in the Treatment of VLUs in a Real World Setting
Koullias GJ, Bain MA, Sabolinski ML
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as “will,” “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “extend,” “continue” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2019. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About
Press and Media Inquiries:Susan Frodigh sfrodigh@organo.com Investor Inquiries:Westwicke Partners Mike Piccinino , CFA OrganoIR@westwicke.com 443-213-0500
Source: Organogenesis Holdings Inc.